Great Science
Deep Compassion
Real Impact
Leveraging our long-standing neuroscience
expertise to develop medicines that
make a difference.
Featured News
September 23, 2024
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep E...
Responsible Growth
Our most recent Corporate Responsibility Report, highlighting activities that took place in 2023, showcases Alkermes' commitment to acting as a responsible corporate citizen across a range of policies, programs and practices.
Culture of Excellence
Our employees' dedication to patients and our communities is foundational to our culture. Hear how our team members contribute to building an organization dedicated to creating real impact.
Notable Recognition
We are honored to be recognized as an employer of choice in the life sciences industry. Visit our Awards & Recognition page to see the latest accolades bestowed on Alkermes, based on the results of a third-party survey shared with our U.S.-based employees.
R&D Pipeline
We apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We are currently focused on developing these investigational candidates.
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
-
Olanzapine and samidorphan
-
Schizophrenia and Bipolar I Disorder (Pediatric)
Phase 3
OverviewOlanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.
Clinical TrialsOlanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
-
-
ALKS 2680
-
Narcolepsy Type 1
Phase 2
-
Narcolepsy Type 2
Phase 2
-
Idiopathic Hypersomnia
Phase 1
OverviewALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.
Clinical TrialsALKS 2680 is currently being evaluated in Vibrance-1, a phase 2 study in adults with narcolepsy type 1, and Vibrance-2, a phase 2 study in adults with narcolepsy type 2.
For more information about these studies, please visit vibrancestudies.com (for U.S. audiences only) or the respective clinicaltrials.gov listings:- Vibrance-1: clinicaltrials.gov/study/NCT06358950
- Vibrance-2: clinicaltrials.gov/study/NCT06555783
-
-
Orexin Agonists
-
Neuroscience Indications
Preclinical
-
Neuroscience Indications
Discovery
OverviewAdditional orexin 2 receptor agonists are in discovery and preclinical research for the treatment of other neurological and psychiatric disorders.
-
